1 with moderate-to-severe rhinitis than FP and azelastine.

2 3]) more than FP (-5.1 [SD, 4.9], P < .001), azelastine (-4.4 [SD, 4.8], P < .001), or placebo (-3.0

3                The results demonstrated that azelastine, 6 mg twice per day, can reduce the need for

4 bitor of mast cell degranulation, but not by azelastine, a histamine receptor 1 antagonist, or by ket

5  efficacy of MP29-02 (a novel formulation of azelastine and fluticasone propionate [FP]) in patients

6  with 2 first-line therapies (ie, intranasal azelastine and intranasal FP) in this population.

7 ess commonly used in clinical practice (i.e. azelastine, chlorpheniramine, hydroxyzine, and ketotifen

8                                          The azelastine group also had a statistically significantly

9                   Compared with placebo, the azelastine group had a statistically significantly great

10                           MP-AzeFlu combines azelastine hydrochloride, FP and a novel formulation in

11 valuate the corticosteroid-sparing effect of azelastine in patients with chronic bronchial asthma.

12 atment with histamine receptor-1 antagonist, azelastine prevented the early effect of nasal secretion

13 otal of 193 subjects received either 6 mg of azelastine twice per day or placebo (in a 2:1 ratio) in

14 n inhaled corticosteroids (4.9 puffs/day for azelastine versus 3.1 puffs/day for placebo; p < or = 0.

15 aseline level (53 and 31%, respectively, for azelastine versus 34 and 14%, respectively, for placebo;